|
1
|
Foroni L, Wilson G, Gerrard G, Mason J,
Grimwade D, White HE, de Castro DG, Austin S, Awan A, Burt E, et
al: Guidelines for the measurement of BCR-ABL1 transcripts in
chronic myeloid leukaemia. Br J Haematol. 153:179–1790. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stella S, Gottardi EM, Favout V, Barragan
Gonzalez E, Errichiello S, Vitale SR, Fava C, Luciano L, Stagno F,
Grimaldi F, et al: The Q-LAMP method represents a valid and rapid
alternative for the detection of the BCR-ABL1 rearrangement in
Philadelphia-positive leukemias. Int J Mol Sci. 20:61062019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jajosky AN and Lichtman MA: Uncommon
phenotypes of BCR::ABL1-positive chronic myelogenous leukemia.
Haematologica. 110:1912–1920. 2025.PubMed/NCBI
|
|
4
|
Breccia M: Atypical CML: Diagnosis and
treatment. Hematology Am Soc Hematol Educ Program. 2023:476–482.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yan Z, Shi L, Li W, Liu W, Galderisi C,
Spittle C, Spittle C and Li J: A novel Next-generation sequencing
assay for the identification of BCR::ABL1 Transcript type and
accurate and sensitive detection of TKI-resistant mutations. J Appl
Lab Med. 9:886–900. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cross NCP, Ernst T, Branford S, Cayuela
JM, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich
JP, Hehlmann R, et al: European LeukemiaNet laboratory
recommendations for the diagnosis and management of chronic myeloid
leukemia. Leukemia. 37:2150–2167. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Leske IB and Hantschel O: The e13a3 (b2a3)
and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib.
Leukemia. 38:2041–2045. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen Z: The e1a3 BCR-ABL1 fusion
transcript in Philadelphia chromosome-positive acute lymphoblastic
leukaemia: A case report. Hematology. 28:21860402023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baccarani M, Castagnetti F, Gugliotta G,
Rosti G, Soverini S, Albeer A and Pfirrmann M; International
BCR-ABL Study Group, : The proportion of different BCR-ABL1
transcript types in chronic myeloid leukemia. An international
overview. Leukemia. 33:1173–1183. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ding L, Chen Q, Chen K, Jiang Y, Li G,
Chen Q, Bai D, Gao D, Deng M, Zhang H and Xu B: Simvastatin
potentiates the cell-killing activity of imatinib in
imatinib-resistant chronic myeloid leukemia cells mainly through
PI3K/AKT pathway attenuation and Myc downregulation. Eur J
Pharmacol. 913:1746332021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Y, Zhang Y, Meng X, Chen S, Wang T,
Zhang L and Ma X: Chronic myeloid leukemia with two rare fusion
gene transcripts of atypical BCR::ABL: A case report and literature
review. Medicine (Baltimore). 103:e367282024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schäfer V, White HE, Gerrard G, Möbius S,
Saussele S, Franke GN, Mahon FX, Talmaci R, Colomer D, Soverini S,
et al: Assessment of individual molecular response in chronic
myeloid leukemia patients with atypical BCR-ABL1 fusion
transcripts: Recommendations by the EUTOS cooperative network. J
Cancer Res Clin Oncol. 147:3081–3089. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hoffmann VS, Baccarani M, Hasford J,
Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D,
Ossenkoppele G, Zaritskey A, et al: Treatment and outcome of 2904
CML patients from the EUTOS population-based registry. Leukemia.
31:593–60. 20171 View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hughes T, Deininger M, Hochhaus A,
Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC,
Druker BJ, et al: Monitoring CML patients responding to treatment
with tyrosine kinase inhibitors: Review and recommendations for
harmonizing current methodology for detecting BCR-ABL transcripts
and kinase domain mutations and for expressing results. Blood.
108:28–37. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin X, Huang H and Chen P: Retrospective
analysis of the clinical features of 172 patients with
BCR-ABL1-negative chronic myeloproliferative neoplasms. Mol
Cytogenet. 13:82020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang Z, Wang W, Toruner GA, Hu S, Fang H,
Xu J, You MJ, Medeiros LJ, Khoury JD and Tang G: Optical genome
mapping for detection of BCR::ABL1-another tool in our toolbox.
Genes (Basel). 15:13572024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu B, Zhang W and Ma H: Complete
cytogenetic response to Nilotinib in a chronic myeloid leukemia
case with a rare e13a3(b2a3) BCR-ABL fusion transcript: A case
report. Mol Med Rep. 13:2635–2638. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Avila M and Meric-Bernstam F:
Next-generation sequencing for the general cancer patient. Clin Adv
Hematol Oncol. 17:447–454. 2019.PubMed/NCBI
|
|
19
|
Sorokin M, Rabushko E, Rozenberg JM,
Mohammad T, Seryakov A, Sekacheva M and Buzdin A: Clinically
relevant fusion oncogenes: Detection and practical implications.
Ther Adv Med Oncol. 14:175883592211441082022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee H, Seo J, Shin S, Lee ST and Choi JR:
Development and validation of sensitive BCR::ABL1 fusion gene
quantitation using next-generation sequencing. Cancer Cell Int.
23:1062023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang X, Sun H, Su Y and Yi H: Long-term
molecular remission after treatment with imatinib in a chronic
myeloid leukemia patient with extreme thrombocytosis harboring rare
e14a3 (b3a3) BCR::ABL1 transcript: A case report. Curr Oncol.
29:8171–8179. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Blachly JS, Walter RB and Hourigan CS: The
present and future of measurable residual disease testing in acute
myeloid leukemia. Haematologica. 107:2810–2822. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Denk D, Bradtke J, König M and Strehl S:
PAX5 fusion genes in t(7;9)(q11.2;p13) leukemia: A case report and
review of the literature. Mol Cytogenet. 7:132014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kosik P, Skorvaga M and Belyaev I:
Incidence of preleukemic fusion genes in healthy subjects.
Neoplasma. 63:659–672. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Elgehama A, Chen W, Pang J, Mi S, Li J,
Guo W, Wang X, Gao J, Yu B, Shen Y and Xu Q: Blockade of the
interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to
overcome Imatinib-resistance of chronic myeloid leukemia cells.
Cancer Lett. 372:82–88. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Szuber N, Orazi A and Tefferi A: Chronic
neutrophilic leukemia and atypical chronic myeloid leukemia: 2024
update on diagnosis, genetics, risk stratification, and management.
Am J Hematol. 99:1360–1387. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ha J, Cheong JW, Shin S, Lee ST and Choi
JR: Chronic myeloid leukemia with rare variant b2a3 (e13a3)
BCR-ABL1 fusion. Ann Lab Med. 36:287–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hai A, Kizilbash NA, Zaidi SHH, Alruwaili
J and Shahzad K: Differences in structural elements of Bcr-Abl
oncoprotein isoforms in Chronic Myelogenous Leukemia.
Bioinformation. 10:108–114. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gross AW, Zhang X and Ren R: Bcr-Abl with
an SH3 deletion retains the ability to induce a myeloproliferative
disease in mice, yet c-Abl activated by an SH3 deletion induces
only lymphoid malignancy. Mol Cell Biol. 19:6918–6928. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu LG, Tanaka H, Ito K, Kyo T, Ito T and
Kimura A: Chronic myelogenous leukemia with e13a3 (b2a3) type of
BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and
a3. Am J Hematol. 74:268–272. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Burmeister T, Schwartz S, Taubald A, Jost
E, Lipp T, Schneller F, Diedrich H, Thomssen H, Mey UJ, Eucker J,
et al: Atypical BCR-ABL mRNA transcripts in adult acute
lymphoblastic leukemia. Haematologica. 92:1699–1702. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Crampe M, Kearney L, O'Brien D, Bacon CL,
O'Shea D and Langabeer SE: Molecular monitoring in adult
philadelphia Chromosome-positive acute lymphoblastic leukemia with
the variant e13a3 BCR-ABL1 fusion. Case Rep Hematol.
2019:96350702019.PubMed/NCBI
|
|
33
|
Phan CL, Tan SN, Tan SM, Kadir SSSA, Ramli
NLM, Lim TO and Ng CC: A variant e13a3 BCR-ABL1 fusion transcript
in refractory adult B-cell acute lymphoblastic leukemia achieving
complete remission with CAR-Tcell therapy. Cancer Genet.
250-251:20–24. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Duan MH, Li H and Cai H: A rare e13a3
(b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic
myeloid leukemia: The challenges in diagnosis and monitoring
minimal residual disease (MRD). Leuk Res. 59:8–11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Waclaw J, Sacha T and Stoklosa T: Imatinib
in the treatment of chronic myeloid leukemia: Current perspectives
on optimal dose. Blood and Lymphatic Cancer: Targets Ther.
5:101–108. 2015.
|
|
36
|
Fava C, Rege-Cambrin G and Saglio G:
Imatinib: The First-Line CML Therapy. Chronic Myeloid Leukemia
[Internet]. Hehlmann R: Cham: Springer International Publishing;
pp. 49–59. 2021, https://doi.org/10.1007/978-3-030-71913-5_4
View Article : Google Scholar
|
|
37
|
McCarron SL, Langabeer SE, Bolger K,
Haslam K, Crampe M, Kelly J and Morrell R: Molecular response to
imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1
fusion. Med Oncol. 32:4522015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Marzocchi G, Castagnetti F, Luatti S,
Baldazzi C, Stacchini M, Gugliotta G, Amabile M, Specchia G,
Sessarego M, Giussani U, et al: Variant Philadelphia
translocations: Molecular-cytogenetic characterization and
prognostic influence on frontline imatinib therapy, a GIMEMA
Working Party on CML analysis. Blood. 117:6793–6800. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lim TH, Tien SL, Lim P and Lim AST: The
incidence and patterns of BCR/ABL rearrangements in chronic myeloid
leukaemia (CML) using fluorescence in situ hybridisation (FISH).
Ann Acad Med Singap. 34:533–538. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Masuko M, Furukawa T, Abe T, Wada R,
Maruyama S, Kitajima T, Shibasaki Y, Toba K, Okada M and Aizawa Y:
A chronic myeloid leukemia patient with atypical karyotype and
BCR-ABL e13a3 transcript caused by complex chromosome
rearrangement. Int J Hematol. 90:230–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou X, Li MR and Shan NN: Chronic myeloid
leukemia with the e13a3 atypical fusion gene: A case report. Oncol
Lett. 29:3192025. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Soverini S: Resistance mutations in CML
and how we approach them. Hematology Am Soc Hematol Educ Program.
2023:469–475. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xu D, Claudiani S, Naresh K, Mucklow S,
Neelakantan P, Yebra E, Apperley JF, Khorashad J and Milojkovic D:
Blast crisis of chronic myeloid leukemia with plasmacytoid
dendritic cell phenotype associated with a rare fusion transcript,
e13a3 BCR-ABL1. Leuk Lymphoma. 60:3090–3091. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Massimino M, Stella S, Tirrò E, Consoli
ML, Pennisi MS, Puma A, Vitale SR, Romano C, Zammit V, Stagno F, et
al: Efficacy of dasatinib in a very elderly CML patient expressing
a rare E13a3 Bcr-Abl1 fusion transcript: A case report. Anticancer
Res. 39:3949–3954. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang YL, Bagg A, Pear W, Nowell PC and
Hess JL: Chronic myelogenous leukemia: Laboratory diagnosis and
monitoring. Genes Chromosomes Cancer. 32:97–11. 20011 View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Caldemeyer L, Dugan M, Edwards J and Akard
L: Long-term side effects of tyrosine kinase inhibitors in chronic
myeloid leukemia. Curr Hematol Malig Rep. 11:71–79. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Narra RK, Flynn KE and Atallah E: Chronic
myeloid leukemia-the promise of tyrosine kinase inhibitor
discontinuation. Curr Hematol Malig Rep. 12:415–4123. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Santos FPS and Ravandi F: Advances in
treatment of chronic myelogenous Leukemia-new treatment options
with tyrosine kinase inhibitors. Leuk Lymphoma. 50 (Suppl
2):S16–S26. 2009. View Article : Google Scholar
|
|
49
|
Hughes TP, Mauro MJ, Cortes JE, Minami H,
Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, et al:
Asciminib in chronic myeloid leukemia after ABL kinase inhibitor
failure. N Engl J Med. 381:2315–2326. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Haddad FG, Issa GC, Jabbour E and Yilmaz
M: Ponatinib for the treatment of adult patients with resistant or
intolerant Chronic-phase chronic myeloid leukemia. Expert Opin
Pharmacother. 23:751–758. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cortes JE, Sasaki K, Kim DW, Hughes TP,
Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, et
al: Asciminib monotherapy in patients with chronic-phase chronic
myeloid leukemia with the T315I mutation after ≥1 prior tyrosine
kinase inhibitor: 2-year follow-up results. Leukemia. 38:1522–1533.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Singh VK and Coumar MS: Chronic myeloid
leukemia: Existing therapeutic options and strategies to overcome
drug resistance. Mini Rev Med Chem. 19:333–345. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lyu X, Yang J, Wang X, Hu J, Liu B, Zhao
Y, Guo Z, Liu B, Fan R and Song Y: A novel BCR-ABL1 fusion gene
identified by next-generation sequencing in chronic myeloid
leukemia. Mol Cytogenet. 9:472016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chisti MM and Sanders DS: Chronic myeloid
leukemia with b3a3 (e14a3) fusion: A rare BCR/ABL rearrangement
presenting with thrombocytosis-Does MTHFR polymorphism matter. Case
Rep Oncol. 11:485–492. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Vaniawala S, Acharya A, Parekh H and
Mukhopadhyaya PN: Rare e14a3 (b3a3) BCR-ABL fusion in chronic
myeloid leukemia in India: The threats and challenges in monitoring
minimal residual disease (MRD). Anal Cell Pathol (Amst). 36:85–92.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Massimino M, Stella S, Tirrò E, Consoli
ML, Pennisi MS, Puma A, Vitale SR, Romano C, Zammit V, Stagno F, et
al: Rapid decline of Philadelphia-positive metaphases after
nilotinib treatment in a CML patient expressing a rare e14a3
BCR-ABL1 fusion transcript: A case report. Oncol Lett.
18:2648–2653. 2019.PubMed/NCBI
|
|
57
|
Jinawath N, Norris-Kirby A, Smith BD,
Gocke CD, Batista DA, Griffin CA and Murphy KM: A rare e14a3 (b3a3)
BCR-ABL fusion transcript in chronic myeloid leukemia: Diagnostic
challenges in clinical laboratory practice. J Mol Diagn.
11:359–363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
O'Brien SG, Guilhot F, Larson RA, Gathmann
I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A,
Hughes T, et al: Imatinib Compared with Interferon and Low-dose
cytarabine for newly diagnosed chronic-phase chronic myeloid
leukemia. N Engl J Med. 348:994–1004. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Farhat-Maghribi S, Habbal W and Monem F:
Frequency of BCR-ABL transcript types in Syrian CML patients. J
Oncol. 2016:84208532016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Martinez-Serra J, Del Campo R, Gutierrez
A, Antich JL, Ginard M, Durán MA, Bento L, Ros T, Amat JC, Vidal C,
et al: Chronic myeloid leukemia with an e1a3 BCR-ABL fusion
protein: Transformation to lymphoid blast crisis. Biomark Res.
2:142014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sun H, Yan Z and Zhang S: Three atypical
BCR/ABL transcripts detected simultaneously in a
Philadelphia-positive acute lymphoblastic leukemia patient showing
resistance to tyrosine kinase inhibitors. Int J Hematol.
117:134–136. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Shin SY, Cho JH, Kim HJ, Jang JH, Lee ST
and Kim SH: Two cases of acute lymphoblastic leukemia with an e1a3
BCR-ABL1 fusion transcript. Ann Lab Med. 35:159–161. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Manzella L, Tirrò E, Vitale SR, Puma A,
Consoli ML, Tambè L, Pennisi MS, DI Gregorio S, Romano C, Tomarchio
C, et al: Optimal response in a patient with CML expressing
BCR-ABL1 E6A2 fusion transcript with nilotinib therapy: A case
report. In Vivo. 34:1481–1486. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Miyashita N, Onozawa M, Suto K, Fujisawa
S, Okazaki N, Hidaka D, Ohigashi H, Yasumoto A, Sugita J, Hashimoto
D, et al: Aleukemic extramedullary blast crisis as an initial
presentation of chronic myeloid leukemia with E1A3 BCR-ABL1 fusion
transcript. Intern Med. 61:1049–1054. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Crampe M, Haslam K, Groarke E, Kelleher E,
O'Shea D, Conneally E and Langabeer SE: Chronic myeloid leukemia
with an e6a2 BCR-ABL1 fusion transcript: Cooperating mutations at
blast crisis and molecular monitoring. Case Rep Hematol.
2017:90717022017.PubMed/NCBI
|
|
66
|
Beel KA, Lemmens J, Vranckx H, Maertens J
and Vandenberghe P: CML with e6a2 BCR-ABL1 transcript: An
aggressive entity? Ann Hematol. 90:1241–1243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Hochhaus A, Breccia M, Saglio G,
García-Gutiérrez V, Réa D, Janssen J and Apperley J: Expert
Opinion-management of chronic myeloid leukemia after resistance to
second-generation tyrosine kinase inhibitors. Leukemia.
34:1495–1502. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Hochhaus A, Ernst T, Eigendorff E and La
Rosée P: Causes of resistance and treatment choices of second- and
third-line treatment in chronic myelogenous leukemia patients. Ann
Hematol. 94 (Suppl 2):S133–S140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Roman J, Jimenez A, Barrios M, Castillejo
JA, Maldonado J and Torres A: E1A3 as a unique, naturally occurring
BCR-ABL transcript in an indolent case of chronic myeloid
leukaemia. Br J Haematol. 114:635–637. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Chen R and Chen B: The role of dasatinib
in the management of chronic myeloid leukemia. Drug Des Devel Ther.
9:773–779. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Sheets JW, Eulitt P, He R, Olteanu H,
Coombs CC, Foster MC, Montgomery ND and Zeidner JF: Philadelphia
chromosome-positive acute myeloid leukemia with e1a3 BCR-ABL1
fusion transcript. Hemasphere. 4:e4842020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Qiang X, Wen Q, Li J, Chen S, Tao T, Zhang
H, Wang P, Peng X, Feng Y and Zhang X: Isolated central nervous
system infiltrated and progressed to acute myeloid leukemia from
chronic myeloid leukemia with e1a3 BCR-ABL1 transcript: A rare case
report and literature review. Cancer Manag Res. 17:35–43. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Soverini S, Albano F, Bassan R, Fabbiano
F, Ferrara F, Foà R, Olivieri A, Rambaldi A, Rossi G, Sica S, et
al: Next-generation sequencing for BCR-ABL1 kinase domain mutations
in adult patients with Philadelphia chromosome-positive acute
lymphoblastic leukemia: A position paper. Cancer Med. 9:2960–2970.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Kearney L, Crampe M and Langabeer SE:
Frequency and spectrum of atypical BCR-ABL1 transcripts in chronic
myeloid leukemia. Exp Oncol. 42:78–79. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Arana-Trejo RM, Ruíz Sánchez E,
Ignacio-Ibarra G, Báez de la Fuente E, Garces O, Gómez Morales E,
Castro Granados M, Ovilla Martínez R, Rubio-Borja ME, Solís Anaya
L, et al: BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican
patients with chronic myeloid leukaemia (CML). Clin Lab Haematol.
24:145–150. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Gong Z, Medeiros LJ, Cortes JE, Zheng L,
Khoury JD, Wang W, Tang G, Loghavi S, Luthra R, Yang W, et al:
Clinical and prognostic significance of e1a2 BCR-ABL1 transcript
subtype in chronic myeloid leukemia. Blood Cancer J. 7:e5832017.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Bhreathnach Ú, Kearney L and Langabeer SE:
Prevalence of atypical BCR-ABL1 transcript types in adult
Philadelphia chromosome-positive acute lymphoblastic leukemia:
Implications for measurable residual disease. Hematol Transfus Cell
Ther. 44:130–131. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wasif K, Wasif N and Saif MW:
Imatinib-induced ototoxicity in a patient with gastrointestinal
stromal tumor (GIST). Cureus. 8:e8482016.PubMed/NCBI
|
|
79
|
Shin H, Choi SY, Kee KM, Kim SH, Yang SY,
Jung SY, Noh H, Zang DY, Kim DW and Lee JI: Comprehensive analyses
of safety and efficacy toward individualizing imatinib dosage in
patients with chronic myeloid leukemia. Int J Hematol. 111:417–426.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Joensuu H, Trent JC and Reichardt P:
Practical management of tyrosine kinase inhibitor-associated side
effects in GIST. Cancer Treat Rev. 37:75–88. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Radojkovic M, Ristic S, Pavlovic S and
Colovic M: Molecular response to imatinib in patient with Ph
negative p190 BCR-ABL transcript positive chronic myeloid leukemia
with cyclic leukocytosis. Leuk Res. 33:e10–e12. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Sun J, Hu R, Han M, Tan Y, Xie M, Gao S
and Hu JF: Mechanisms underlying therapeutic resistance of tyrosine
kinase inhibitors in chronic myeloid leukemia. Int J Biol Sci.
20:175–181. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Moore FR, Yang F and Press RD: Detection
of BCR-ABL1 kinase domain mutations causing imatinib resistance in
chronic myelogenous leukemia. Methods Mol Biol. 999:25–39. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Ben-Batalla I, Erdmann R, Jørgensen H,
Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus JL,
Rankin S and Clark RE: Axl blockade by BGB324 inhibits BCR-ABL
tyrosine kinase Inhibitor-sensitive and -resistant chronic myeloid
leukemia. Clin Cancer Res. 23:2289–2300. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Yeung DT, Shanmuganathan N and Hughes TP:
Asciminib: A new therapeutic option in chronic-phase CML with
treatment failure. Blood. 139:3474–3479. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Cioccio J and Claxton D: Therapy of acute
myeloid leukemia: Therapeutic targeting of tyrosine kinases. Expert
Opin Investig Drugs. 28:337–349. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Pan Q, Lu Y, Xie L, Wu D, Liu R, Gao W,
Luo K, He B and Pu Y: Recent advances in boosting EGFR tyrosine
kinase inhibitors-based cancer therapy. Mol Pharm. 20:829–852.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Illmer T and Ehninger G: FLT3 kinase
inhibitors in the management of acute myeloid leukemia. Clin
Lymphoma Myeloma. 8 (Suppl 1):S24–S34. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Cui Q, Liang P, Dai H, Cui W, Cai M, Ding
Z, Ma Q, Yin J, Li Z, Liu S, et al: Case report: CD38-directed
CAR-T cell therapy: A novel immunotherapy targeting CD38-positive
blasts overcomes TKI and chemotherapy resistance of myeloid chronic
myeloid leukemia in blastic phase. Front Immunol. 13:10129812022.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Khan AM, Munir A, Asrani R and Najjar S:
Acute myeloid leukemia with Philadelphia chromosome,
near-tetraploidy, and 5q deletion. Cureus. 11:e56062019.PubMed/NCBI
|
|
91
|
Ohsaka A, Shiina S, Kobayashi M, Kudo H
and Kawaguchi R: Philadelphia Chromosome-positive chronic myeloid
leukemia expressing p190(BCR-ABL). Intern Med. 41:1183–1187. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Tucker D, Hamilton MS, Kerr JP, Wickham C
and Hunter H: Lytic bone disease as the presenting feature of
Philadelphia-positive monosomy 7 myelodysplasia progressing to
acute myeloid leukaemia. Gene. 501:219–221. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Stella S, Massimino M, Tirrò E, Vitale SR,
Scalise L, Leotta S, Pennisi MS, Puma A, Romano C, Stagno F, et al:
B-ALL relapses after autologous stem cell transplantation
associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A
case report. Anticancer Res. 39:431–435. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Balatzenko G, Guenova M, Kalinova I,
Belcheva M, Hristozova H and Kaleva V: Simultaneous occurrence of
ETV6-RUNX1 and BCR-ABL1 (e1a2) transcripts in a child with B-cell
acute lymphoblastic leukemia. Cancer Genet Mar. 206:97–101. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Langabeer SE, Crampe M, Haslam K, Kelly J
and Cahill MR: Sustained clinical remission despite suboptimal
molecular response to imatinib in e1a2 BCR-ABL chronic myeloid
leukemia. Leuk Res. 34:e176–e177. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Agirre X, Román-Gómez J, Vázquez I,
Jiménez-Velasco A, Larráyoz MJ, Lahortiga I, Andreu EJ, Márquez J,
Beltrán de Heredia JM, Odero MD, et al: Coexistence of different
clonal populations harboring the b3a2 (p210) and e1a2 (p190)
BCR-ABL1 fusion transcripts in chronic myelogenous leukemia
resistant to imatinib. Cancer Genet Cytogenet. 60:22–26. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Ai DI, Liu W, Lu G, Patel KP and Chen ZI:
Extramedullary blast crisis as initial presentation in chronic
myeloid leukemia with the e1a2 BCR-ABL1 transcript: A case report.
Mol Clin Oncol. 3:1319–1322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Dupont M, Jourdan E and Chiesa J:
Identification of E6A2 BCR-ABL fusion in a Philadelphia-positive
CML. Leukemia. 14:2011–2012. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Staal-Viliare A, Latger-Cannard V, Rault
JP, Didion J, Grégoire MJ, Bologna S, Witz B, Jonveaux P, Lecompte
T and Rio Y: A case of de novo acute basophilic leukaemia:
Diagnostic criteria and review of the literature. Ann Biol Clin
(Paris). 64:361–365. 2006.(In French). PubMed/NCBI
|
|
100
|
Zagaria A, Anelli L, Coccaro N, Tota G,
Casieri P, Cellamare A, Impera L, Brunetti C, Minervini A,
Minervini CF, et al: BCR-ABL1 e6a2 transcript in chronic myeloid
leukemia: Biological features and molecular monitoring by droplet
digital PCR. Virchows Arch. 467:357–363. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Popovici C, Cailleres S, David M,
Lafage-Pochitaloff M, Sainty D and Mozziconacci MJ: E6a2 BCR-ABL
fusion with BCR exon 5-deleted transcript in a Philadelphia
positive CML responsive to Imatinib. Leuk Lymphoma. 46:1375–1377.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Breccia M, Cannella L, Diverio D, Streponi
P, Nanni M, Stefanizzi C, Natalino F, Mecarocci S and Alimena G:
Isolated thrombocytosis as first sign of chronic myeloid leukemia
with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete
response to imatinib. Leuk Res. 32:177–180. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Rohon P, Divoka M, Calabkova L, Mojzikova
R, Katrincsakova B, Rusinakova Z, Lapcikova A, Raida L, Faber E,
Jarosova M, et al: Identification of e6a2 BCR-ABL fusion in a
Philadelphia-positive CML with marked basophilia: Implications for
treatment strategy. Biomed Pap Med Fac Univ Palacky Olomouc Czech
Repub. 155:187–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Torres F, Ivanova-Dragoeva A, Pereira M,
Veiga J, Rodrigues AS, Sousa AB, Tavares P and Fernandes AR: An
e6a2 BCR-ABL fusion transcript in a CML patient having an iliac
chloroma at initial presentation. Leuk Lymphoma. 48:1034–1037.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Schnittger S, Bacher U, Kern W, Haferlach
T, Hertenstein B and Haferlach C: A new case with rare e6a2 BCR-ABL
fusion transcript developing two new resistance mutations during
imatinib mesylate, which were replaced by T315I after subsequent
dasatinib treatment. Leukemia. 22:856–858. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
McCarron SL, Kelly J, Coen N, McCabe S,
Fay M, O'Dwyer M, Hayden PJ and Langabeer SE: A novel e8a2 BCR-ABL1
fusion with insertion of RALGPS1 exon 8 in a patient with relapsed
Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk
Lymphoma. 52:919–921. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Burmeister T, Bullinger L and le Coutre P:
The recurrent atypical e8a2 BCR::ABL1 transcript with insertion of
an inverted 55 base pair ABL1 Intron 1b sequence: A detailed
molecular analysis. Acta Haematol. 146:413–418. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Mroczkowska A, Jaźwiec B, Urbańska-Rakus
J, Szymanowska S, Tessmann A, Pająk S, Machnik K, Haus O and Wróbel
T: A case report of pediatric acute lymphoblastic leukemia with
e8a2 BCR/ABL1 fusion transcript. BMC Med Genomics. 15:202022.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Riva E, Manrique Arechavaleta G, De
Almeida C, Costa V, Fernandez Del Campo M, Ifran González S and
Uriarte R: A novel e8a2 BCR-ABL1 fusion with insertion of MAST2
exon 2 in a four-way translocation t (1;17;9;22) (p35;q24;q44;q11)
in a patient with chronic myeloid leukemia. Leuk Lymphoma.
57:203–205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zhang Y, Cheng Z, Yan WZ, Liu SF, Hu CH
and Zhang GS: Molecular characterization and therapeutic reaction
to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1
transcript with a somatic mutation in TP53BP2 and cadherin-10
genes. Leuk Lymphoma. 59:233–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Branford S and Apperley JF: Measurable
residual disease in chronic myeloid leukemia. Haematologica.
107:2794–809. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Cundell MJ, Hutter LH, Nunes Bastos R,
Poser E, Holder J, Mohammed S, Novak B and Barr FA: A PP2A-B55
recognition signal controls substrate dephosphorylation kinetics
during mitotic exit. J Cell Biol. 214:539–554. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Gelens L, Qian J, Bollen M and Saurin AT:
The importance of Kinase-phosphatase integration: Lessons from
mitosis. Trends Cell Biol. 28:6–21. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Jin C, Zhu X, Xiao M, Liu S, Liu X, Liu J,
Xu X, Yi S and Meng L: A Novel e8a2BCR-ABL1 fusion transcript
without insertion sequence in a patient with chronic myeloid
leukemia. Ann Lab Med. 38:169–171. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Langabeer SE, McCarron SL, Kelly J,
Krawczyk J, McPherson S, Perera K and Murphy PT: Chronic myeloid
leukemia with e19a2 BCR-ABL1 transcripts and marked thrombocytosis:
The role of molecular monitoring. Case Rep Hematol.
2012:4587162012.PubMed/NCBI
|
|
116
|
Tchirkov A, Couderc JL, Périssel B, Goumy
C, Regnier A, Uhrhammer N, Verrelle P and Berger M: Major molecular
response to imatinib in a patient with chronic myeloid leukemia
expressing a novel form of e8a2 BCR-ABL transcript. Leukemia.
20:167–168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
May PC, Reid AG, Robinson ME, Khorashad
JS, Milojkovic D, Claudiani S; Genomics England Research
Consortium, ; Willis F, Apperley JF and Innes AJ: FISH-negative
BCR::ABL1-positive e19a2 chronic myeloid leukaemia: The most
cryptic of insertions. BMC Med Genomics. 16:1722023. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Cea M, Cirmena G, Garuti A, Rocco I,
Palermo C, Cagnetta A, Moran E, Colombo N, Grasso R, Fugazza G, et
al: A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia
responding to dasatinib. Leuk Res. 34:e240–e242. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Popovici C, Charbonnier A, Gisserot O,
Aguilon P, Rémy V, Olschwang S and Mozziconacci MJ: Y253H mutation
appearing in a micro-BCR-ABL (e19a2) CML. Leuk Res. 32:361–362.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Ikeda K, Harada-Shirado K, Matsumoto H,
Noji H, Ogawa K and Takeishi Y: Molecular response of e19a2
BCR-ABL1 chronic myeloid leukemia with double Philadelphia
chromosome to dasatinib. J Clin Oncol. 34:e130–e133. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Crampe M, Garry J, Langabeer SE and Murphy
PT: Sustained molecular response with nilotinib in
Imatinib-intolerant chronic myeloid leukaemia with an e19a2
BCR-ABL1 fusion. Hematol Oncol Stem Cell Ther. 9:168–169. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Ernst P, Rinke J, Franke GN, Dicker F,
Haferlach T, Ernst T and Hochhaus A: Treatment-free remission after
third-line therapy with asciminib in chronic myeloid leukemia with
an atypical e19a2 BCR::ABL1 transcript and T315I mutation.
Leukemia. 38:2037–2040. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Mondal BC, Majumdar S, Dasgupta UB,
Chaudhuri U, Chakrabarti P and Bhattacharyya S: e19a2 BCR-ABL
fusion transcript in typical chronic myeloid leukaemia: A report of
two cases. J Clin Pathol. 59:1102–1103. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
McCarron SL, Maher K, Kelly J, Ryan MF and
Langabeer SE: Rapid evolution to blast crisis associated with a
Q252H ABL1 kinase domain mutation in e19a2 BCR-ABL1 chronic myeloid
leukaemia. Case Rep Hematol. 2013:4907402013.PubMed/NCBI
|
|
125
|
Kajiguchi T, Okuno S, Ohno T and Abe A:
Molecular response to nilotinib in a patient with
imatinib-intolerant e19a2-positive chronic myeloid leukemia. Intern
Med. 53:2801–2804. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Santos FK de S and Maia CN: Patients with
sickle cell disease taking hydroxyurea in the hemocentro regional
de Montes Claros. Rev Bras Hematol Hemoter. 33:105–109. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Krakoff IH: Clinical and Pharmacologic
Effects of Hydroxyurea. Antineoplastic and Immunosuppressive
Agents: Part II [Internet]. Sartorelli AC and Johns DG: Springer;
Berlin, Heidelberg: pp. 789–792. 1975, https://doi.org/10.1007/978-3-642-65806-8_43
View Article : Google Scholar
|
|
128
|
Kamidani R, Chiba N, Kuroda A, Uchida A
and Okada H: Successful therapeutic leukapheresis for chronic
myeloid leukemia identified by persistent erection: A case report.
Cureus. 16:e613512024.PubMed/NCBI
|
|
129
|
Oshikawa G, Kurosu T, Arai A, Murakami N
and Miura O: Clonal evolution with double Ph followed by
tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2
transcript in transformation. Cancer Genet Cytogenet. 199:56–61.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Stella S, Massimino M, Tirrò E, Vitale SR,
Accurso V, Puma A, Pennisi MS, DI Gregorio S, Romano C, DI Raimondo
F, et al: Detection and clinical implications of a novel BCR-ABL1
E12A2 Insertion/deletion in a CML patient expressing the E13A2
isoform. Anticancer Res. 39:6965–6971. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Alikian M, Gale RP, Apperley JF and Foroni
L: Molecular techniques for the personalised management of patients
with chronic myeloid leukaemia. Biomol Detect Quantif. 11:4–20.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Suttorp M, Millot F, Sembill S, Deutsch H
and Metzler M: Definition, epidemiology, pathophysiology, and
essential criteria for diagnosis of pediatric chronic myeloid
leukemia. Cancers (Basel). 13:7982021. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Wu CC, Beird HC, Zhang J and Futreal PA:
FusionPathway: Prediction of pathways and therapeutic targets
associated with gene fusions in cancer. PLoS Comput Biol.
14:e10062662018. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Pretzsch T, Progscha S and Burmeister T:
Diagnostic ambiguity caused by an atypical e18a2 BCR::ABL1
transcript in a chronic myeloid leukemia patient. Case Rep Hematol.
2024:94391342024.PubMed/NCBI
|
|
135
|
Sheng HX, Zhou LN, Chen JL, Hu GL, Wang
QH, Gao DG, Liao L, Yang Y, Sun T, Chen H and Zhang B: Concurrence
of e18a2 and e19a2 in Ph (+) chronic myelogenous leukemia: A case
report and literature review. Zhonghua Xue Ye Xue Za Zhi.
38:799–802. 2017.(In Chinese). PubMed/NCBI
|
|
136
|
van der Velden VHJ, Beverloo HB, Hoogeveen
PG and Zwaan CM: A novel BCR-ABL fusion transcript (e18a2) in a
child with chronic myeloid leukemia. Leukemia. 21:833–835. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Naumann N, Bross-Bach U, Seifarth W,
Fabarius A, Hofmann WK, Saußele S and Spiess B: A new aberrantly
spliced BCR-ABL1 transcript variant (e13a1) identified in routine
monitoring using different quantitative reverse transcription
polymerase chain reaction techniques in a patient with chronic
myeloid leukemia. EJHaem. 3:1339–1342. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Callet-Bauchu E, Salles G, Gazzo S, Dalle
S, Berger F and Hayette S: Identification of a novel e8/a4 BCR/ABL
fusion transcript in a case of a transformed Sézary syndrome.
Haematologica. 92:1277–1278. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Wang H, Han C, Gong B, Liu Y, Liu K, Gu R,
Wang Y, Wei H, Mi Y, Liu B and Wang J: Clinical features and
treatment response to TKIs in chronic myeloid leukemia patients
with atypical BCR::ABL1 transcripts. Leuk Res. 155:1077332025.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Zangrando A, Intini F, te Kronnie G and
Basso G: Validation of NG2 antigen in identifying BP-ALL patients
with MLL rearrangements using qualitative and quantitative flow
cytometry: A prospective study. Leukemia. 22:858–861. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Park IJ, Lim YA, Lee WG, Park JS, Kim HC,
Lee HJ and Cho SR: A case of chronic myelogenous leukemia with e8a2
fusion transcript. Cancer Genet Cytogenet. 185:106–108. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Lee J, Kim DS, Lee HS, Choi SI and Cho YG:
Concurrence of e1a2 and e19a2 BCR-ABL1 fusion transcripts in a
typical case of chronic myeloid leukemia. Ann Lab Med. 37:74–76.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Bennour A, Beaufils N, Sennana H, Meddeb
B, Saad A and Gabert J: E355G mutation appearing in a patient with
e19a2 chronic myeloid leukaemia resistant to imatinib. J Clin
Pathol. 63:737–740. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Langabeer SE, McCarron SL, Carroll P,
Kelly J, O'Dwyer M and Conneally E: Molecular response to first
line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid
leukemia. Leuk Res. 35:e169–e170. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Jeon EK, Lim J, Kim M, Yahng SA, Lee SE,
Cho BS, Kim YJ, Kim HJ, Min CK, Cho SG, et al: The first case of
acute lymphoblastic leukemia with the e19a2 BCR-ABL1 transcript:
Imatinib therapy followed by unrelated donor transplantation
induces a durable molecular response. Leukemia. 25:366–367. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Qin YZ, Jiang Q, Jiang H, Lai YY, Shi HX,
Chen WM, Yu L and Huang XJ: Prevalence and outcomes of uncommon
BCR-ABL1 fusion transcripts in patients with chronic myeloid
leukaemia: Data from a single centre. Br J Haematol. 182:693–700.
2018. View Article : Google Scholar : PubMed/NCBI
|
